Cancer Research The Future of Cancer Research: Science and Patient Impact  Cancer Health Disparities Conference 2009
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 56, 299-304, January 15, 1996]
© 1996 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by de Groene, E. M.
Right arrow Articles by Horbach, G. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by de Groene, E. M.
Right arrow Articles by Horbach, G. J.

Development of Human Cytochrome P450-expressing Cell Lines: Application in Mutagenicity Testing of Ochratoxin A

Els M. de Groene1, Ine G. A. M. Hassing, Maarten J. Blom, Willem Seinen, Johanna Fink-Gremmels and G. Jean Horbach

Research Institute of Toxicology [E. M. d. G., I. G. A. M. H., W. S., G. J. H.], Department of Veterinary Pharmacy, Pharmacology, and Toxicology [M. J. B., J. F. G.], Utrecht University, Yalelaan 2, P.O. Box 80.176, NL-3508 TD Utrecht, the Netherlands

With the aim to assess the involvement of distinct forms of cytochrome P450 enzymes in the activation of procarcinogens, we have developed by means of retroviral infection a series of NIH/3T3 cell lines stably expressing human CYP1A1, CYP1A2, CYP2C10, CYP2D6, and CYP2E1 cDNA. The levels of cytochrome P450 enzyme activities were determined using specific substrates. An increase in specific catalytic activity could be observed in all cell lines compared to background activity in vector-infected cells. Furthermore, we developed a test system in which we are able to combine P450-expressing cells with a shuttle vector containing the lacZ' gene, which serves as a reporter gene for mutations.

Using this system, we investigated the cytotoxicity and mutagenicity of the mycotoxin ochratoxin A. Natural occurrence of ochratoxin A in food commodities has been linked to an increased incidence of urinary tract tumors in certain geographic regions. Although biotransformation seems to play a crucial role in ochratoxin A toxicity, the possible contribution of metabolites to genotoxicity and carcinogenicity remained unelucidated.

We have demonstrated that the mutation frequency of ochratoxin A was increased dependent upon concentration in NIH/3T3 cell lines, stably expressing human CYP1A1, CYP1A2, CYP2C10, and CYP3A4. In contrast, neither in vector-infected NIH/3T3 cells nor in CYP2D6- and CYP2E1-expressing cells was an increase of mutation frequency observed.

1 To whom requests for reprints should be addressed. Phone: 31-30-2535400; Fax: 31-30-2535077.

Received 8/ 1/95. Accepted 11/ 8/95.




This article has been cited by other articles:


Home page
MutagenesisHome page
L. Arbillaga, A. Azqueta, O. Ezpeleta, and A. L. d. Cerain
Oxidative DNA damage induced by Ochratoxin A in the HK-2 human kidney cell line: evidence of the relationship with cytotoxicity
Mutagenesis, January 1, 2007; 22(1): 35 - 42.
[Abstract] [Full Text] [PDF]


Home page
Toxicol SciHome page
H. Zepnik, A. Pahler, U. Schauer, and W. Dekant
Ochratoxin A-Induced Tumor Formation: Is There a Role of Reactive Ochratoxin A Metabolites?
Toxicol. Sci., January 1, 2001; 59(1): 59 - 67.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1996 by the American Association for Cancer Research.